New drug: FDA approves IND-P276

Nicholas Piramal India Ltd announced that the Company has received USFDA approval for its Investigational New Drug application of its lead cancer compound 'P-276-00' to treat Multiple Myeloma.

Clinical trials will start at Harvard University's Dana Farber Cancer Institute.

P 276-00 is a new chemical entity that blocks pathways necessary for cancer cell growth and survival.

The Clinical Studies will be coordinated by Dr Kenneth Anderson. The Principal Investigator of the trial will be Dr. Noopur Raje, M.D., at the Dana Farber - Massachusetts General Hospital. Dr. Noopur Raje is part of the Jerome Lipper Cancer center at the Dana-Farber Cancer Institute. St. Vincent's Hospital in New York and Emory University Medical Center in Atlanta will also participate in the study.